These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2770 related articles for article (PubMed ID: 8011699)

  • 1. Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma.
    Lu C; Kerbel RS
    Curr Opin Oncol; 1994 Mar; 6(2):212-20. PubMed ID: 8011699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine and paracrine regulation by cytokines and growth factors in melanoma.
    Lázár-Molnár E; Hegyesi H; Tóth S; Falus A
    Cytokine; 2000 Jun; 12(6):547-54. PubMed ID: 10843728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathogenic role of growth factors in melanoma.
    Richmond A
    Semin Dermatol; 1991 Sep; 10(3):246-55. PubMed ID: 1931574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype.
    Bani MR; Rak J; Adachi D; Wiltshire R; Trent JM; Kerbel RS; Ben-David Y
    Cancer Res; 1996 Jul; 56(13):3075-86. PubMed ID: 8674065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor progression in the human melanocytic system.
    Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
    Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
    Keller-Melchior R; Schmidt R; Piepkorn M
    J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin.
    Reichrath J; Seyfried P; Braun R; Müller SM; Baum HP; Bahmer FA
    Dermatology; 1997; 194(2):136-9. PubMed ID: 9094461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular correlates in the progression of normal melanocytes to melanomas.
    Halaban R
    Semin Cancer Biol; 1993 Jun; 4(3):171-81. PubMed ID: 8318693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic pathways to melanoma tumorigenesis.
    Hussein MR
    J Clin Pathol; 2004 Aug; 57(8):797-801. PubMed ID: 15280398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of metastasis suppressor gene product, nm23 protein, is not inversely correlated with the tumour progression in human malignant melanomas.
    Saitoh K; Takahashi H; Yamamoto M; Kishi H; Parsons PG
    Histopathology; 1996 Dec; 29(6):497-505. PubMed ID: 8971556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
    Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
    Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions.
    Nouman GS; Anderson JJ; Mathers ME; Leonard N; Crosier S; Lunec J; Angus B
    Histopathology; 2002 Apr; 40(4):360-6. PubMed ID: 11943021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genetic factors in the development and progression of malignant melanoma].
    Rünger TM; Bröcker EB
    Hautarzt; 1995 Jun; 46(6):394-9. PubMed ID: 7642382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional evidence of novel tumor suppressor genes for cutaneous malignant melanoma.
    Parris CN; Harris JD; Griffin DK; Cuthbert AP; Silver AJ; Newbold RF
    Cancer Res; 1999 Feb; 59(3):516-20. PubMed ID: 9973191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma.
    Herbst RA; Gutzmer R; Matiaske F; Mommert S; Casper U; Kapp A; Weiss J
    Int J Cancer; 1999 Jan; 80(2):205-9. PubMed ID: 9935201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of growth factors and their receptors in the development and progression of melanoma.
    Shih IM; Herlyn M
    J Invest Dermatol; 1993 Feb; 100(2 Suppl):196S-203S. PubMed ID: 8381840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the nm23 metastasis-suppressor gene product in skin tumors.
    Kanitakis J; Euvrard S; Bourchany D; Faure M; Claudy A
    J Cutan Pathol; 1997 Mar; 24(3):151-6. PubMed ID: 9085150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis and significance of the malignant 'eclipse' during the progression of primary cutaneous human melanomas.
    Kerbel RS; Kobayashi H; Graham CH; Lu C
    J Investig Dermatol Symp Proc; 1996 Apr; 1(2):183-7. PubMed ID: 9627714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth control by tumor suppressors in malignant melanoma.
    Coleman A; Robertson G; Lugo TG
    Receptor; 1995; 5(1):9-19. PubMed ID: 7613487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth factor and cytogenetic abnormalities in cultured nevi and malignant melanomas.
    Richmond A; Fine R; Murray D; Lawson DH; Priest JH
    J Invest Dermatol; 1986 Mar; 86(3):295-302. PubMed ID: 3745955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 139.